RARE DISEASE
Neurodegeneration with brain iron accumulation
Neurodegeneration with brain iron accumulation
Neurodegeneration with brain iron accumulation
Synonyms: NBIA
Synonyms: NBIA
Synonyms: NBIA
Drug discovery
2
drugs
With orphan designations
Overview
Neurodegeneration with brain iron accumulation (NBIA) encompasses rare inherited disorders marked by iron deposition in the basal ganglia, leading to progressive extrapyramidal symptoms (dystonia, parkinsonism), spasticity, cognitive decline, and retinal degeneration [1][2][15]. Diagnosis relies on MRI showing characteristic iron accumulation (e.g., "eye of the tiger" sign in PKAN) and genetic testing for causative mutations (e.g., PANK2, PLA2G6, CP) [2][6][14]. Most forms lack curative treatments, focusing on symptom management and supportive care [10][12].
Population
Prevalence <1/1,000,000, with onset ranging from infancy to adulthood [15][19]
Autosomal recessive inheritance in 80% of cases (e.g., PKAN, PLAN); X-linked (BPAN) and dominant subtypes (neuroferritinopathy) occur [1][14]
Common subtypes: PKAN (35-50%), PLAN (20%), MPAN (6-10%), and BPAN (1-2%) [18][19]
Burden
Rapid functional decline in childhood-onset cases, often requiring wheelchairs by adolescence [6][7][14]
Reduced life expectancy (10-12 years post-diagnosis) due to dysphagia-related complications [6][7]
High socioeconomic impact from lifelong care needs and limited disease-modifying therapies [14][19]
Therapies
Iron chelation: Deferiprone reduces basal ganglia iron on MRI, but clinical benefits remain uncertain [3][8][12]
Symptomatic control: Baclofen, trihexyphenidyl, botulinum toxin, and deep brain stimulation for dystonia; levodopa for parkinsonism [7][12][14]
Supportive care: Multidisciplinary approach with physical, occupational, and speech therapies [2][12][14]
Categories: rare genetic diseases, rare neurological diseases
Research Papers
293 drug discovery papers about Neurodegeneration with brain iron accumulation, with 2 first-in-class and 10 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
293 drug discovery papers about Neurodegeneration with brain iron accumulation, with 2 first-in-class and 10 next-in-class emerging drug candidates forecasted to outperform the average preclinical success rate. Recent publications:
2026-07-10 | Therapeutic Advances in Major NBIA Disorders: Current Strategies and Translational Challenges
Neurodegeneration with brain iron accumulation (NBIA) comprises a group of rare genetic movement disorders characterized by progressive neurological deterioration, dystonia, parkinsonism, spasticity, and abnormal iron deposition in the basal ganglia. Although iron accumulation is the shared neuroradiological hallmark, most NBIA genes do not directly regulate iron metabolism. Instead, major NBIA forms arise from disruption of distinct but converging cellular pathways, including coenzyme A (CoA) biosynthesis, lipid metabolism, mitochondrial function, and autophagy. This narrative review aims to examine the pathogenic mechanisms of major NBIA disorders, namely pantothenate kinase-associated neurodegeneration (PKAN), COASY protein-associated neurodegeneration (CoPAN), PLA2G6-associated neurodegeneration (PLAN), mitochondrial membrane protein-associated neurodegeneration (MPAN), and beta-propeller protein-associated neurodegeneration (BPAN), and how these insights are guiding therapeutic development. Preclinical strategies aimed at restoring CoA metabolism, improving mitochondrial function, limiting lipid peroxidation, modulating autophagy, or correcting the underlying genetic defect have shown encouraging results, although none have yet reached robust clinical validation. Clinical translation remains limited by disease rarity, clinical heterogeneity, absence of validated biomarkers, and preclinical models that only partially recapitulate human pathology. Advancing the field will depend on earlier molecular diagnosis, biomarkers capable of tracking disease stage, and trial designs suited to ultra-rare populations. NBIA thus offers a paradigm for how mechanistic classification of a genetically defined disease group can redirect therapeutic strategy away from a shared radiological feature and toward pathway-specific intervention.
2026-07-10 | Precision Medicine in Neurodegeneration with Brain Iron Accumulation (NBIA) Disorders: An Update on Emerging Treatments.
Neurodegeneration with Brain Iron Accumulation (NBIA) is a heterogeneous group of heritable, mostly recessive, progressive neurodegenerative diseases characterized by iron deposition in the basal ganglia and brainstem. There are no solid global epidemiological data on prevalence and incidence of NBIA subtypes, but registry data and expert opinion suggest PKAN, BPAN, PLAN, and MPAN are the most common subtypes. NBIA disorders present with a wide spectrum of clinical symptoms, including movement disorders (dystonia, parkinsonism, chorea), pyramidal involvement (eg, spasticity), speech and cognitive deficits, motor and cognitive slowing, and ocular abnormalities. Treatment remains symptomatic, though several new drugs are in development. Following our review published in 2021, this article provides an updated summary of recent developments. We discuss the rationale of new compounds, summarize clinical trials or-in their absence-preclinical studies for NBIA subtypes. The article is divided into two sections: one section on general approaches based on the shared feature of increased iron in the brain; and the second section on tailor-made, mechanistic treatments for the various NBIA subtypes targeting the specific molecular and cellular pathways of the affected enzyme including gene therapy. In summary, randomized controlled trials in NBIA have not yet demonstrated substantial benefit, neither for iron removal, in general, which appears to be clinically ineffective in most subtypes, except aceruloplasminemia; nor for subtype-specific approaches. Several ongoing studies are exploring more dedicated compounds in this exciting field.
2026-06-17 | Pathophysiology, biological models and new therapeutic approaches in β-Propeller Associated Neurodegeneration.
Neurodegeneration with brain iron accumulation (NBIA) encompasses a set of rare disorders that present a diagnostic challenge due to their genetic and clinical diversity, with treatment options currently limited to symptom alleviation. One subtype, β-Propeller Associated Neurodegeneration (BPAN), results from pathogenic variants in the WDR45 gene on the X chromosome. This condition is marked by iron accumulation in the globus pallidus and substantia nigra, alongside early onset developmental delays, seizures, and motor impairments. The WDR45 gene produces the WDR45 protein, which plays a key role in the creation and maturation of autophagosomes-crucial components of the autophagy process, a cellular mechanism vital to the organism's proper function. In BPAN, reduced autophagy correlates with mitochondrial dysfunction, impaired antioxidant defenses, elevated lipid peroxidation, buildup of lipofuscin granules, and disrupted iron metabolism. However, the precise relationships between these pathological issues remain unclear. There is no curative treatment for BPAN, therefore care focuses on palliation and symptom management through a multidisciplinary approach. Nonetheless, research into various therapeutic strategies is ongoing, including gene therapy to correct the genetic anomaly and methods to influence pathological pathways like autophagy deficiency, lipid peroxidation, and iron accumulation. A novel approach has recently been suggested, aimed at reactivating the inactive X chromosome in females with BPAN.
2026-07-10 | Therapeutic Advances in Major NBIA Disorders: Current Strategies and Translational Challenges
Neurodegeneration with brain iron accumulation (NBIA) comprises a group of rare genetic movement disorders characterized by progressive neurological deterioration, dystonia, parkinsonism, spasticity, and abnormal iron deposition in the basal ganglia. Although iron accumulation is the shared neuroradiological hallmark, most NBIA genes do not directly regulate iron metabolism. Instead, major NBIA forms arise from disruption of distinct but converging cellular pathways, including coenzyme A (CoA) biosynthesis, lipid metabolism, mitochondrial function, and autophagy. This narrative review aims to examine the pathogenic mechanisms of major NBIA disorders, namely pantothenate kinase-associated neurodegeneration (PKAN), COASY protein-associated neurodegeneration (CoPAN), PLA2G6-associated neurodegeneration (PLAN), mitochondrial membrane protein-associated neurodegeneration (MPAN), and beta-propeller protein-associated neurodegeneration (BPAN), and how these insights are guiding therapeutic development. Preclinical strategies aimed at restoring CoA metabolism, improving mitochondrial function, limiting lipid peroxidation, modulating autophagy, or correcting the underlying genetic defect have shown encouraging results, although none have yet reached robust clinical validation. Clinical translation remains limited by disease rarity, clinical heterogeneity, absence of validated biomarkers, and preclinical models that only partially recapitulate human pathology. Advancing the field will depend on earlier molecular diagnosis, biomarkers capable of tracking disease stage, and trial designs suited to ultra-rare populations. NBIA thus offers a paradigm for how mechanistic classification of a genetically defined disease group can redirect therapeutic strategy away from a shared radiological feature and toward pathway-specific intervention.
2026-07-10 | Precision Medicine in Neurodegeneration with Brain Iron Accumulation (NBIA) Disorders: An Update on Emerging Treatments.
Neurodegeneration with Brain Iron Accumulation (NBIA) is a heterogeneous group of heritable, mostly recessive, progressive neurodegenerative diseases characterized by iron deposition in the basal ganglia and brainstem. There are no solid global epidemiological data on prevalence and incidence of NBIA subtypes, but registry data and expert opinion suggest PKAN, BPAN, PLAN, and MPAN are the most common subtypes. NBIA disorders present with a wide spectrum of clinical symptoms, including movement disorders (dystonia, parkinsonism, chorea), pyramidal involvement (eg, spasticity), speech and cognitive deficits, motor and cognitive slowing, and ocular abnormalities. Treatment remains symptomatic, though several new drugs are in development. Following our review published in 2021, this article provides an updated summary of recent developments. We discuss the rationale of new compounds, summarize clinical trials or-in their absence-preclinical studies for NBIA subtypes. The article is divided into two sections: one section on general approaches based on the shared feature of increased iron in the brain; and the second section on tailor-made, mechanistic treatments for the various NBIA subtypes targeting the specific molecular and cellular pathways of the affected enzyme including gene therapy. In summary, randomized controlled trials in NBIA have not yet demonstrated substantial benefit, neither for iron removal, in general, which appears to be clinically ineffective in most subtypes, except aceruloplasminemia; nor for subtype-specific approaches. Several ongoing studies are exploring more dedicated compounds in this exciting field.
2026-06-17 | Pathophysiology, biological models and new therapeutic approaches in β-Propeller Associated Neurodegeneration.
Neurodegeneration with brain iron accumulation (NBIA) encompasses a set of rare disorders that present a diagnostic challenge due to their genetic and clinical diversity, with treatment options currently limited to symptom alleviation. One subtype, β-Propeller Associated Neurodegeneration (BPAN), results from pathogenic variants in the WDR45 gene on the X chromosome. This condition is marked by iron accumulation in the globus pallidus and substantia nigra, alongside early onset developmental delays, seizures, and motor impairments. The WDR45 gene produces the WDR45 protein, which plays a key role in the creation and maturation of autophagosomes-crucial components of the autophagy process, a cellular mechanism vital to the organism's proper function. In BPAN, reduced autophagy correlates with mitochondrial dysfunction, impaired antioxidant defenses, elevated lipid peroxidation, buildup of lipofuscin granules, and disrupted iron metabolism. However, the precise relationships between these pathological issues remain unclear. There is no curative treatment for BPAN, therefore care focuses on palliation and symptom management through a multidisciplinary approach. Nonetheless, research into various therapeutic strategies is ongoing, including gene therapy to correct the genetic anomaly and methods to influence pathological pathways like autophagy deficiency, lipid peroxidation, and iron accumulation. A novel approach has recently been suggested, aimed at reactivating the inactive X chromosome in females with BPAN.
Access all drug discovery articles and probability of success in trials forecasts:
Access all drug discovery articles and probability of success in trials forecasts:
Drug Discovery Landscape
2 orphan drug designations for Neurodegeneration with brain iron accumulation.
2 orphan drug designations for Neurodegeneration with brain iron accumulation.
Drug | Therapy type | Regulator | Orphan designation | Approval | Sponsor |
|---|---|---|---|---|---|
Deferiprone | small molecules | EMA | 2018-06-27 | — | Chiesi Farmaceutici S.p.A. |
deferiprone | small molecules | FDA | 2017-06-15 | — | Chiesi USA, Inc. |
Let's accelerate rare disease drug discovery
Let's accelerate drug discovery
Get access to Explority AI's forecasts to outperform average preclinical success rates. Whether you're expanding your R&D pipeline, evaluating a partnership, or simply have a question — we'd love to hear from you.